2023 guidance reiterated
For Q1 2023, the company reported revenues of EUR 1.3bn (vs EUR 6.4bn in Q1 2022), net profit of EUR 0.5bn (vs EUR 3.7bn Q1 2023) and fully diluted earnings per share of EUR 2.05 (vs EUR 14.24 Q1 2023). The differences mainly results from lower sales of Comirnaty. For 2023, BioNTech reiterated prev
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.